App-Quantinova.ai

Utilization of adjuvant trastuzumab for T1a,b N0 HER2+ breast cancer in Ontario.

Andrea Eisen - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

A study of the anatomic distribution of brain metastases in HER2+ breast cancer: Implications for hippocampal avoidance PCI.

Jacob Witt - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Differentiation of overall survival by breast cancer tumor subtype following stereotactic radiosurgery for brain metastasis.

Eunpi Cho - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A nonrandomized phase II study of dose-dense paclitaxel and cyclophosphamide (PC) in early-stage breast cancer (EBC).

Kailash Mosalpuria - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancer-A collaborative study of RTOG and KROG (NCT01622868).

David M. Peereboom - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.

Tejal Amar Patel - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab emtansine

Biomarker panel (TheraPrint) analyzed as a predictor of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Peter D. Beitsch - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).

Denise A. Yardley - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ramucirumab

The effects of omega-3 fatty acids on chemotherapy-induced neuropathy and inflammation in patients with breast cancer.

Ali Esfahani - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Paclitaxel

Prognostic effect of eribulin-induced liver dysfunction in metastatic breast cancer.

Takayuki Kobayashi - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ursodeoxycholic acid

First safety results of an international phase II study evaluating oral vinorelbine as a single agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial).

Guenther G. Steger - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vinorelbine

Paclitaxel-induced severe sensory peripheral neuropathy is associated with NDRG-1 genetic variant and negative NDRG-1 expression in nerve tissue.

Raghav Sundar - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: A validation study.

Kai Chen - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

Cardiovascular magnetic resonance imaging compared to echocardiogram for detecting doxorubicin-induced cardiotoxicity.

Haleem J. Rasool - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).

Robert Wesolowski - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Effect of overexpression of human kinesin-14 family motor HSET on tumor progression and clinical outcomes in breast cancer patients.

Vaishali Pannu - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario.

Sofia Torres - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

Centrosome declustering agents: Potential interphase-targeting antimetastatic chemotherapeutics.

Vaishali Pannu - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

griseofulvin ultramicrosize tablet

Febrile neutropenia risk with adjuvant TC (docetaxel and cyclophosphamide) regimen: Experience of Brazilian cancer centers.

Joao Paulo Velloso Medrado Santos - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

A randomized phase II trial of upfront docetaxel and vinorelbine followed by either maintenance oral vinorelbine or observation in patients with HER2-negative locally advanced (LA) or metastatic (M) breast cancer (BC).

Fadi Sami Farhat - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vinorelbine

Filters

41730 Abstracts